Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference Post published:October 26, 2022 Post category:Press Release
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression Post published:October 25, 2022 Post category:Press Release
Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs Post published:October 24, 2022 Post category:Press Release
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study Post published:October 24, 2022 Post category:Press Release
Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited Post published:October 24, 2022 Post category:Press Release
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study Post published:October 21, 2022 Post category:Press Release
atai Life Sciences Announces R&D Day Agenda Post published:October 21, 2022 Post category:Press Release
Psilera’s Award-Winning Co-Founders To Be Featured Speakers at Upcoming Industry Conferences Across the Country. Post published:October 20, 2022 Post category:Press Release
Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award Post published:October 20, 2022 Post category:Press Release
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio Post published:October 19, 2022 Post category:Press Release